# Becton Dickinson & Co: Form 10-Q for the period ended Dec 31, 2016

- Company: [Becton Dickinson & Co](/companies/bdx.md) (CIK 10795)
- Form: 10-Q
- Filed: 2017-02-02
- Accepted by EDGAR: Feb 2, 2017, 13:04 ET
- Period: 2016-12-31
- Accession: 0000010795-17-000002
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/10795/000001079517000002/bdx1231201610-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/10795/000001079517000002/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2016-10-01 to 2016-12-31 | $1.47bn | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months, 2016-10-01 to 2016-12-31 | $182.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2016-10-01 to 2016-12-31 | $709.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2016-10-01 to 2016-12-31 | $811.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2016-10-01 to 2016-12-31 | $95.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2016-10-01 to 2016-12-31 | $131.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2016-10-01 to 2016-12-31 | $562.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-10-01 to 2016-12-31 | $2.58 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2016-10-01 to 2016-12-31 | $2.64 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2016-10-01 to 2016-12-31 | 217,739,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2016-10-01 to 2016-12-31 | $315.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2016-10-01 to 2016-12-31 | $112.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2016-10-01 to 2016-12-31 | $156.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months, 2016-10-01 to 2016-12-31 | $220.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2016-12-31 | $919.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-12-31 | $5.19bn | us-gaap:AssetsCurrent |
| Total assets | at 2016-12-31 | $24.32bn | us-gaap:Assets |
| Current liabilities | at 2016-12-31 | $4.57bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2016-12-31 | $9.04bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2016-12-31 | $1.97bn | us-gaap:DebtCurrent |
| Shareholders' equity | at 2016-12-31 | $7.58bn | us-gaap:StockholdersEquity |
| Shares outstanding | at 2016-12-31 | 212,825,085 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 43,273 characters.

The following commentary should be read in conjunction with the condensed consolidated financial statements and accompanying notes. Within the tables presented throughout this discussion, certain columns may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

### Company Overview

Becton, Dickinson and Company (“BD”) is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company's organizational structure is based upon two principal business segments, BD Medical (“Medical”) and BD Life Sciences (“Life Sciences”).

BD’s products are manufactured and sold worldwide. Our products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives. We organize our operations outside the United States as follows: Europe; EMA (which includes the Commonwealth of Independent States, the Middle East and Africa); Greater Asia (which includes Japan and Asia Pacific); Latin America (which includes Mexico, Central America, the Caribbean, and South America); and Canada. We continue to pursue growth opportunities in emerging markets, which include the following geographic regions: Eastern Europe, the Middle East, Africa, Latin America and certain countries within Asia Pacific. We are primarily focused on certain countries whose healthcare systems are expanding, in particular, China and India.

### Overview of Financial Results and Financial Condition

For the three months ended December 31, 2016, worldwide revenues of $2.922 billion decreased 2.1% from the prior-year period. The decrease in revenue reflected the unfavorable impact from divestitures, primarily the Respiratory Solutions business divestiture, of approximately 7%. Revenues in the first quarter of fiscal year 2017 also reflected volume growth for our continuing businesses of approximately 6% and an unfavorable foreign currency translation impact of approximately 1%. Pricing did not materially impact first quarter revenues. Additional disclosures regarding our divestiture of the Respiratory Solutions business are provided in Note 9 in the Notes to Condensed Consolidated Financial Statements. Volume growth in the first quarter of fiscal year 2017 reflected the following:

- Medical segment volume growth in the first quarter reflected earlier than anticipated timing of capital placements by the Medication Management Solutions unit and order placements for the Pharmaceutical Systems unit. Medical segment volume growth in the first quarter additionally reflected the Medication and Procedural Solutions unit's sales of flush and infection prevention products, the Pharmaceutical Systems unit's sales of self-injections systems, as well as the Diabetes Care unit’s sales of pen needles.
- Life Sciences segment volume growth in the first quarter primarily reflected the Preanalytical Systems unit's sales of safety-engineered products in emerging markets, the Diagnostic Systems unit's sales of certain platforms, and the Biosciences unit's sales of its advanced bioprocessing platform and research instruments. Life Sciences segment volume growth in the first quarter was partially offset by an unfavorable comparison of the current period's international revenues in the Biosciences unit to the prior-year period.
- Worldwide sales of safety-engineered products reflected growth that was attributable to both segments. First quarter sales in the United States of safety-engineered devices of $454 million increased 1.6% and first quarter international sales of safety-engineered devices of $308 million grew 6.3% over the prior year’s period, inclusive of an estimated 1.3% unfavorable impact due to foreign currency translation.

We continue to invest in research and development, geographic expansion, and new product promotions to drive further revenue and profit growth. Our ability to sustain our long-term growth will depend on a number of factors, including our ability to expand our core business (including geographical expansion), develop innovative new products, and continue to improve operating efficiency and organizational effectiveness. While the economic environment for the healthcare industry has generally stabilized, pricing pressures continue for some of our products. Healthcare utilization has stabilized and slightly improved in the United States; however, any destabilization in the future could adversely impact our U.S. businesses. Additionally, macroeconomic challenges in Europe continue to constrain healthcare utilization, although we currently view the environment as stable. In emerging markets, the Company’s growth is dependent primarily on government funding for healthcare systems.

Our financial position remains strong, with cash flows from operating activities totaling $315 million in the first three months of fiscal year 2017. At December 31, 2016, we had $0.9 billion in cash and equivalents and short-term investments. We continued to return value to our shareholders in the form of dividends. During the first three months of fiscal year 2017, we paid cash dividends of $156 million. We also repurchased approximately $220 million of our common stock under an accelerated share repurchase agreement during the first three months of fiscal year 2017. Additional disclosures regarding this share repurchase agreement are provided in Note 4 in the Notes to Condensed Consolidated Financial Statements.

Each reporting period, we face currency exposure that arises from translating the results of our worldwide operations to the U.S. dollar at exchange rates that fluctuate from the beginning of such period. The ongoing relative strength of the U.S. dollar resulted in an unfavorable foreign currency translation impact to our revenue and earnings growth during the first quarter of fiscal year 2017. We evaluate our results of operations on both a reported and a foreign currency-neutral basis, which excludes the impact of fluctuations in foreign currency exchange rates. As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a foreign currency-neutral basis in addition to reported results helps improve investors’ ability to understand our operating results and evaluate our performance in comparison to prior periods. Foreign currency-neutral ("FXN") information compares results between periods as if exchange rates had remained constant period-over-period. We use results on a foreign currency-neutral basis as one measure to evaluate our performance. We calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior-period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. These results should be considered in addition to, not as a substitute for, results reported in accordance with U.S. generally accepted accounting principles ("GAAP"). Results on a foreign currency-neutral basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with U.S. GAAP.

### Results of Operations

### Medical Segment

The following summarizes first quarter Medical revenues by organizational unit, as well as first quarter Medical sales of safety-engineered products:

| (Millions of dollars) | Three months ended December 31, 2016 | 2015 | Total Change (B) | Estimated FX Impact | FXN Change (B) |
| --- | ---: | ---: | ---: | ---: | ---: |
| Medication and Procedural Solutions | $869 | $848 | 2.4% | (1.0)% | 3.4% |
| Medication Management Solutions (A) | 601 | 545 | 10.2% | (0.8)% | 11.0% |
| Diabetes Care | 267 | 256 | 4.6% | 0.1% | 4.5% |
| Pharmaceutical Systems | 227 | 197 | 15.6% | 0.1% | 15.5% |
| Respiratory Solutions (A) | — | 208 | NM | —% | NM |
| Total Medical Revenues | $1,964 | $2,054 | (4.4)% | (0.6)% | (3.8)% |
| Medical segment safety-engineered products | $483 | $467 | 3.4% | (0.3)% | 3.7% |

(A) The presentation of prior-period amounts has been revised to conform with the presentation of current-period amounts, which does not separately present an immaterial adjustment for the amortization of a deferred revenue balance write-down relating to the CareFusion acquisition.

(B) "NM" denotes that the percentage is not meaningful.

The decrease in total Medical segment revenues in the first quarter of 2017 compared with the prior-year period reflected the divestiture of the Respiratory Solutions business, as previously discussed. Medical segment revenue growth in the first quarter was favorably impacted by placements of both dispensing and infusion capital by the Medication Management Solutions unit, a portion of which occurred earlier than anticipated in the current fiscal year. Earlier than anticipated order placements in Europe for the Pharmaceutical Systems unit also favorably impacted Medical segment revenue growth in the first quarter of 2017. Medical segment revenues in the current-year period additionally reflected the Medication and Procedural Solutions unit's sales of flush and infection prevention products as well as the Pharmaceutical Systems unit's sales of self-injections systems. Medical segment revenues in the first quarter of 2017 also reflected the Diabetes Care unit’s sales of pen needles, which were favorably impacted by the timing of U.S. customer orders.

Medical segment operating income for the first quarter was as follows:

| (Millions of dollars) | Three months ended December 31, 2016 | 2015 |
| --- | ---: | ---: |
| Medical segment operating income | $548 | $465 |
| Segment operating income as % of Medical revenues | 27.9% | 22.6% |

The Medical segment's operating income is driven by its performance with respect to gross profit margin and operating expenses. Gross profit margin was higher in the first quarter of 2017 as compared with the first quarter of 2016 primarily due to the divestiture of the Respiratory Solutions business, which had products with lower gross profit margins. Gross profit margin also reflected lower manufacturing costs resulting from continuous improvement projects which enhanced the efficiency of our operations, partially offset by higher raw material costs. Selling and administrative expense as a percentage of revenues for the first quarter of fiscal year 2017 was lower as a result of the divestiture of the Respiratory Solutions business as this business generally had a lower operating margin. Selling administrative expense as a percentage of revenues in the current-year period additionally benefited from the suspension of the medical device excise tax imposed under the U.S. Patient Protection Affordable Care Act. Research and development expense as a percentage of revenues was relatively flat in the first quarter of 2017 as compared with the first quarter of 2016.

### Life Sciences Segment

The following summarizes first quarter Life Sciences revenues by organizational unit, as well as first quarter Life Sciences sales of safety-engineered products:

| (Millions of dollars) | Three months ended December 31, 2016 | 2015 | Total Change | Estimated FX Impact | FXN Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Preanalytical Systems | $355 | $344 | 3.3% | (0.9)% | 4.2% |
| Diagnostic Systems | 334 | 313 | 6.4% | —% | 6.4% |
| Biosciences | 270 | 276 | (2.2)% | (0.5)% | (1.7)% |
| Total Life Sciences Revenues | $958 | $933 | 2.7% | (0.5)% | 3.2% |
| Life Sciences segment safety-engineered products | $280 | $270 | 3.5% | (0.9)% | 4.4% |

Life Sciences segment revenues in the first quarter were aided by the Diagnostics Systems unit, which experienced an earlier start to the current year’s influenza season compared to prior year, as well as growth relating to the *BD Kiestra*TM and *BD MAX*TM platforms. The segment’s first quarter revenue growth also reflected sales of the Preanalytical Systems safety-engineered products, primarily in emerging markets. Lastly, within the Biosciences unit, an unfavorable comparison of the current period's international revenues to the prior-year period was partially offset by U.S. sales of its advanced bioprocessing platform and research instruments and reagents.

Life Sciences segment operating income for the first quarter was as follows:

| (Millions of dollars) | Three months ended December 31, 2016 | 2015 |
| --- | ---: | ---: |
| Life Sciences segment operating income | $198 | $202 |
| Segment operating income as % of Life Sciences revenues | 20.7% | 21.6% |

The Life Sciences segment's operating income is driven by its performance with respect to gross profit margin and operating expenses. Gross profit margin in the first quarter of fiscal year 2017 was lower compared with the first quarter of 2016 primarily due to unfavorable foreign currency translation and higher unfavorable manufacturing variances, partially offset by lower manufacturing costs resulting from continuous improvement projects which enhanced the efficiency of our operations. Selling and administrative expense as a percentage of revenues in the first quarter of 2017 was slightly higher compared to the prior-year period reflecting higher shipping costs which were partially offset by the suspension of the medical device excise tax.

Research and development expense as a percentage of revenues was relatively flat in the first quarter of 2017 as compared with the first quarter of 2016.

### Geographic Revenues

BD’s worldwide first quarter revenues by geography were as follows:

| (Millions of dollars) | Three months ended December 31, 2016 | 2015 | Total Change | Estimated FX Impact | FXN Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| United States | $1,630 | $1,691 | (3.6)% | — | (3.6)% |
| International | 1,292 | 1,295 | (0.2)% | (1.3)% | 1.1% |
| Total Revenues | $2,922 | $2,986 | (2.1)% | (0.5)% | (1.6)% |

The Medical segment's U.S. revenues in the first quarter reflected the divestiture of the Respiratory Solutions business, as previously discussed. This impact was partially offset by sales in the Medication Management Solutions unit, which benefited from the favorable timing of capital placements, and in the Diabetes Care unit, which benefited from the favorable timing of customer orders. The Medical segment's U.S. revenues in the first quarter were also aided by revenue growth from the Medication and Procedural Solutions unit's infusion disposable products. U.S. Life Sciences revenue growth in the first quarter of fiscal year 2017 was driven by the Diagnostic Systems unit's higher influenza-related sales as well as sales for the microbiology platform. U.S. Life Sciences segment's revenue growth also reflected the favorable timing of customer orders relative to the advanced bioprocessing platform and sales of research instruments and reagents in the Biosciences unit. The Life Sciences segment's U.S. revenues were unfavorably impacted by limited availability of a product line in the Preanalytical Systems unit.

The Medical segment's international first quarter revenues also reflected the divestiture of the Respiratory Solutions business, partially offset by the favorable timing of customer orders in the Pharmaceutical Systems unit, as previously discussed. International Medical segment revenue growth was aided by the Medication and Procedural Solutions unit's sales of infusion disposable and infection prevention products and the Medication Management Solutions unit's capital placements. The Life Sciences segment's first quarter international revenue growth was aided by the Preanalytical Systems unit's sales of safety-engineered products in emerging markets. International Life Sciences revenue growth in the current-year period was also aided by the Diagnostic Systems unit's sales in Latin America and Asia Pacific as well as higher influenza-related sales, but were offset by an unfavorable comparison of the current period's Biosciences unit's revenues to the prior-year period, as previously discussed.

Emerging market revenues for the first quarter were $456 million, compared with $465 million in the prior year’s quarter, which included approximately $30 million of revenues associated with divested businesses, primarily the Respiratory Solutions business. Emerging market revenues in the current-year period also included an estimated $14 million unfavorable impact due to foreign currency translation. First quarter revenue growth in emerging markets was driven by sales in China and Latin America, which were partially offset by declines in the Middle East and Africa.

### Specified Items

Reflected in the financial results for the first quarters of fiscal years 2017 and 2016 were the following specified items:

| (Millions of dollars) | Three months ended December 31, 2016 | 2015 |
| --- | ---: | ---: |
| Integration costs (A) | 46 | 35 |
| Restructuring costs (A) | 35 | 85 |
| Transaction costs (A) | 6 | — |
| Purchase accounting adjustments (B) | 126 | 153 |
| Litigation-related item (C) | (336) | — |
| Loss on debt extinguishment (D) | 42 | — |
| Total specified items | (81) | 274 |
| Tax impact of specified items | (27) | 79 |
| After-tax impact of specified items | $(54) | $195 |

20

(A) Represents integration, restructuring and transaction costs substantially associated with our fiscal year 2015 acquisition of CareFusion and other portfolio rationalization initiatives. The integration, restructuring and transaction costs were recorded in *Acquisitions and other restructurings.*

(B) Primarily represents non-cash amortization expense associated with acquisition-related identifiable intangible assets. BD’s amortization expense is primarily recorded in *Costs of products sold.*

(C) Represents the reversal of certain reserves related to an appellate court decision recorded in *Other operating income*, as further discussed below.

(D) Represents a loss recognized in *Other (expense) income, net* upon our extinguishment of certain long-term senior notes, as further discussed below

### Gross Profit Margin

Gross profit margin for the first quarter of fiscal year 2017 compared with the prior-year period in 2016 reflected the following impacts:

|  | Three-month period |
| --- | ---: |
| **December 31, 2015 gross profit margin %** | 47.1% |
| Operating performance | 1.7% |
| Impact of divestitures | 0.8% |
| Foreign currency translation | 0.1% |
| **December 31, 2016 gross profit margin %** | 49.7% |

Operating performance in the current-year period reflected lower manufacturing costs resulting from the continuous operations improvement projects discussed above, partially offset by higher raw material costs. Gross profit margin for the first quarter of fiscal year 2017 was favorably impacted by businesses divestitures, primarily the divestiture of the Respiratory Solutions business, which as previously discussed, had products with lower gross profit margins.

### Operating Expenses

A summary of operating expenses for the first quarters of fiscal years 2017 and 2016 is as follows:

| (Millions of dollars) | Three months ended December 31, 2016 | 2015 | Increase (decrease) in basis points |
| --- | ---: | ---: | ---: |
| Selling and administrative expense | $709 | $748 |  |
| % of revenues | 24.3% | 25.1% | (80) |
| Research and development expense | $182 | $187 |  |
| % of revenues | 6.2% | 6.3% | (10) |
| Acquisitions and other restructurings | $87 | $121 |  |
| Other operating income | $(336) | $— |  |

#### Selling and administrative expense

Selling and administrative expense as a percentage of revenues in the current year’s three-month period reflected the divestiture of the Respiratory Solutions business, as this business generally had a lower operating margin, as well as the benefit from the suspension of the medical device excise tax, as previously discussed.

#### Research and development expense

Research and development expense as a percentage of revenues in the three-month period of fiscal year 2017 was relatively flat compared with the prior-year period in 2016 reflecting ongoing investment in new products and platforms.

#### Acquisitions and other restructurings

Costs relating to acquisitions and other restructurings in the three-month periods represented integration, restructuring and transaction costs substantially associated with our fiscal year 2015 acquisition of CareFusion and other portfolio rationalization initiatives. For further disclosures regarding the restructuring costs, refer to Note 10 in the Notes to Condensed Consolidated Financial Statements.

#### Other operating (income) expense, net

Other operating income in the current-year period represented the $336 million reversal of certain reserves related to an appellate court decision which, among other things, reversed an unfavorable antitrust judgment in the Retractable Technologies, Inc. case. Additional disclosures regarding this legal matter are provided Note 5 in the Notes to Condensed Consolidated Financial Statements.

### Nonoperating Income

#### Net interest expense

The components for the first quarters of fiscal years 2017 and 2016 were as follows:

| (Millions of dollars) | Three months ended December 31, 2016 | 2015 |
| --- | ---: | ---: |
| Interest expense | $(95) | $(97) |
| Interest income | 5 | 6 |
| Net interest expense | $(89) | $(91) |

The decrease in interest expense for the three-month period of fiscal year 2017 compared with the prior year's period primarily reflected lower levels of debt as certain senior notes matured in June and November 2016 and we repurchased certain senior notes in December 2016. Additional disclosures regarding this debt repurchase are provided in Note 14 in the Notes to Condensed Consolidated Financial Statements. The decrease in interest income for the three-month period of fiscal year 2017 compared with the prior year’s period primarily reflected lower investment gains on assets related to our deferred compensation plans. The offsetting movement in the deferred compensation plan liability was recorded in *Selling and administrative expense.*

#### Other (expense) income, net

The components for the first quarters of fiscal years 2017 and 2016 were as follows:

| (Millions of dollars) | Three months ended December 31, 2016 | 2015 |
| --- | ---: | ---: |
| Loss on debt extinguishment | $(42) | $— |
| Transition service agreement income, net | 14 | — |
| Losses on undesignated foreign exchange derivatives, net | (4) | — |
| Other | 2 | 6 |
| Other (expense) income, net | $(29) | $6 |

As discussed above, we repurchased certain senior notes in December 2016 and recognized a loss on this extinguishment of debt. The transition service agreement income relates to our divestiture of the Respiratory Solutions business which is further discussed in Note 9 in the Notes to Condensed Consolidated Financial Statements.

### Income Taxes

The income tax rates for the first quarters of fiscal years 2017 and 2016 are provided below.

|  | Three months ended December 31, 2016 | 2015 |
| --- | ---: | ---: |
| Effective income tax rate | 18.9% | 14.0% |
| (Unfavorable) favorable impact, in basis points, from specified items | (190) | 750 |

The increase in the current-year period's effective income tax rate is due to BD's geographical mix of income and the unfavorable tax impact from specified items, which included the reversal of certain reserves related to an appellate court decision, as previously discussed. The unfavorable impact on specified items in the current-year period was partially offset by a $27 million tax benefit recognized upon the settlement of share-based compensation awards during the first quarter of fiscal year 2017, in connection with BD's adoption of new accounting requirements relating to share-based compensation award-related income tax effects. Additional disclosures regarding this adoption are provided in Note 2 in the Notes to Condensed Consolidated Financial Statements.

### Net Income and Diluted Earnings per Share

Net Income and Diluted Earnings per Share for the first quarters of fiscal years 2017 and 2016 were as follows:

|  | Three months ended December 31, 2016 | 2015 |
| --- | ---: | ---: |
| Net Income (Millions of dollars) | $562 | $229 |
| Diluted Earnings per Share | $2.58 | $1.06 |
| Favorable (unfavorable) impact-specified items | $0.25 | $(0.90) |
| Unfavorable impact-foreign currency translation | $(0.01) | $(0.26) |

### Liquidity and Capital Resources

The following table summarizes our condensed consolidated statement of cash flows:

| (Millions of dollars) Net cash provided by (used for) | Three months ended December 31, 2016 | 2015 |
| --- | ---: | ---: |
| Operating activities | $315 | $463 |
| Investing activities | $48 | $(145) |
| Financing activities | $(955) | $(145) |

### Net Cash Flows from Operating Activities

Cash generated from operations, along with available cash and cash equivalents, is expected to be sufficient to fund our normal operating needs for the remainder of fiscal year 2017. Normal operating needs in fiscal year 2017 include working capital, capital expenditures, and cash dividends. The change in net cash provided by operating activities was primarily attributable to net income, as adjusted for depreciation and amortization and other non-cash items. The current period change in operating assets and liabilities was a net use of cash and primarily reflected higher levels of prepaid expenses and lower levels of accounts payable and accrued expenses. The current-year period also reflected the loss recorded upon our extinguishment of certain long-term notes in December 2016, which is included within *Other, net.*

### Net Cash Flows from Investing Activities

Our investments in capital expenditures are focused on projects that enhance our cost structure and manufacturing capabilities, and support our strategy of geographic expansion with select investments in growing markets. Capital expenditure-related cash outflows of $112 million in the first three months of fiscal year 2017, compared with $134 million in the prior-year period, were offset by cash inflows in the current-year period of $167 million from business divestitures.

### Net Cash Flows from Financing Activities

Net cash used for financing activities in the first three months of fiscal year 2017 included cash inflows relating to the issuance of euro-denominated notes in December 2016 and our borrowings during the quarter under our commercial paper program of $1,054 million and $700 million, respectively. Net cash used for financing activities during the first three months of fiscal year 2017 also reflected $2,189 million of cash outflows associated with our repurchase of certain long-term notes in December 2016 and our repayment of 1.75% notes due on November 8, 2016. Additional disclosures regarding our issuance and repurchase of debt during the first quarter of fiscal year 2017 are provided in Note 14 in the Notes to Condensed Consolidated Financial Statements. Net cash used for financing activities in the first three months of fiscal year 2017 also reflected our repurchase of $220 million of common stock under an accelerated share repurchase agreement, as previously discussed.

Certain measures relating to our total debt were as follows:

| (Millions of dollars) | December 31, 2016 | September 30, 2016 |
| --- | ---: | ---: |
| Total debt | $11,017 | $11,551 |
| Short-term debt as a percentage of total debt | 17.9% | 8.7% |
| Weighted average cost of total debt | 3.3% | 3.6% |
| Total debt as a percentage of total capital\* | 55.8% | 57.2% |

\* Represents shareholders’ equity, net non-current deferred income tax liabilities, and debt.

The ratio of short-term debt as a percentage of total debt at September 30, 2016 increased as a result of a $700 million net increase in borrowings under our commercial paper program, our repurchase of certain long-term debt, as previously discussed, and the reclassification, from long-term debt to short-term debt, of notes due in December 2017. These impacts to the ratio of short-term debt as a percentage of total debt were partially offset by the repayment of $500 million of notes due in November 2016 and our issuance of euro-denominated senior notes, also as previously discussed.

### Cash and Short-term Investments

At December 31, 2016, total worldwide cash and short-term investments were approximately $0.9 billion, of which $0.7 billion was held in jurisdictions outside of the United States. We regularly review the amount of cash and short-term investments held outside the United States and currently intend to use such amounts to fund our international operations and their growth initiatives. In addition, if these amounts were repatriated from foreign jurisdictions to the United States, there could be adverse tax consequences.

### Credit Facilities

We have in place a commercial paper borrowing program which allows us to issue a maximum of $1.5 billion in notes and which is available to meet our short-term financing needs, including working capital requirements. Borrowings outstanding under this program were $900 million at December 31, 2016, which reflected a net increase of $700 million from our outstanding balance of commercial paper borrowing at September 30, 2016, as previously discussed.

We also have in place a $1.5 billion syndicated credit facility which provides backup support for our commercial paper program and can also be used for other general corporate purposes. There were no borrowings outstanding under this credit facility at December 31, 2016. During the first quarter of fiscal year 2017, we extended the expiration date of this credit facility to January 2022 from the original expiration date of January 2021. We may issue up to $100 million in letters of credit under this facility and it also includes a provision that enables BD, subject to additional commitments made by the lenders, to access up to an additional $500 million in financing through the facility for a maximum aggregate commitment of $2 billion. The credit facility includes a single financial covenant that requires BD to maintain an interest expense coverage ratio of not less than 5-to-1 for the most recent four consecutive fiscal quarters. We were in compliance with this covenant as of December 31, 2016. We also have informal lines of credit outside the United States.

### Concentrations of Credit Risk

We continually evaluate our accounts receivables for potential collection risks, particularly those resulting from sales to government-owned or government-supported healthcare facilities in certain countries, as payment may be dependent upon the financial stability and creditworthiness of those countries’ national economies. We continually evaluate all governmental receivables for potential collection risks associated with the availability of government funding and reimbursement practices. We believe the current reserves related to all governmental receivables are adequate and that these receivables will not have a material adverse impact on our financial position or liquidity.

### Cautionary Statement Regarding Forward-Looking Statements

BD and its representatives may from time to time make certain forward-looking statements in publicly released materials, both written and oral, including statements contained in filings with the Securities and Exchange Commission, press releases, and our reports to shareholders. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,”, “may”, “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance (including volume growth, sales and earnings per share growth, and changes in cash flows) and statements regarding our strategy for growth, future product development, regulatory approvals, competitive position and expenditures. All statements that address our future operating performance or events or developments that we expect or anticipate will occur in the future are forward-looking statements.

Forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events, developments and operating performance, and speak only as of their dates. Investors should realize that if underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements. Furthermore, we undertake no obligation to update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events and developments or otherwise, except as required by applicable law or regulations.

The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements. For further discussion of certain of these factors, see Item 1A. Risk Factors in our 2016 Annual Report on Form 10-K.

- Weakness in the global economy and financial markets, which could increase the cost of operating our business, weaken demand for our products and services, negatively impact the prices we can charge for our products and services, or impair our ability to produce our products.
- Competitive factors that could adversely affect our operations, including new product introductions (for example, new forms of drug delivery) by our current or future competitors, increased pricing pressure due to the impact of low-cost manufacturers as certain competitors have established manufacturing sites or have contracted with suppliers in low-cost manufacturing locations as a means to lower their costs, patents attained by competitors (particularly as patents on our products expire), and new entrants into our markets.
- The adverse financial impact resulting from unfavorable changes in foreign currency exchange rates.
- Regional, national and foreign economic factors, including inflation, deflation, and fluctuations in interest rates, and their potential effect on our operating performance.
- Our ability to achieve our projected level or mix of product sales, as our earnings forecasts are based on projected sales volumes and pricing of many product types, some of which are more profitable than others.
- Changes in reimbursement practices of third-party payers or adverse decisions relating to our products by such payers, which could reduce demand for our products or the price we can charge for such products.
- The impact of the Patient Protection and Affordable Care Act (the "PPACA") in the United States, which implemented an excise tax on U.S. sales of certain medical devices (which has been suspended until January 1, 2018), and which could result in reduced demand for our products, increased pricing pressures or otherwise adversely affect our business.
- Future healthcare reform in the United States and other countries in which we do business that may involve changes in government pricing and reimbursement policies or other cost containment reforms.
- Changes in domestic and foreign healthcare industry practices that result in a reduction in procedures using our products or increased pricing pressures, including the continued consolidation among healthcare providers and trends toward managed care and healthcare cost containment.
- The impact of changes in U.S. federal laws and policy adopted under the new administration and Congress, including the effect that such changes will have on fiscal and tax policies, the potential repeal of all or portions of the PPACA, and international trade agreements and policies.
- Fluctuations in the cost and availability of oil-based resins and other raw materials, as well as certain components, used in our products, the ability to maintain favorable supplier arrangements and relationships (particularly with respect to sole-source suppliers), and the potential adverse effects of any disruption in the availability of such items.
- Security breaches of our information technology systems or our products, which could impair our ability to conduct business, result in the loss of BD trade secrets or otherwise compromise sensitive information of BD or its customers, suppliers and other business partners, or of customers' patients, or result in product efficacy or safety concerns for certain of our products.
- Difficulties inherent in product development, including the potential inability to successfully continue technological innovation, successfully complete clinical trials, obtain regulatory approvals in the United States and abroad, obtain intellectual property protection for our products, obtain coverage and adequate reimbursement for new products, or gain and maintain market approval of products, as well as the possibility of infringement claims by competitors with respect to patents or other intellectual property rights, all of which can preclude or delay commercialization of a product. Delays in obtaining necessary approvals or clearances from the FDA or other regulatory agencies or changes in the regulatory process may also delay product launches and increase development costs.
- The impact of business combinations, including any volatility in earnings relating to acquisition-related costs, and our ability to successfully integrate any business we may acquire.
- Our ability to penetrate or expand our operations in emerging markets, which depends on local economic and political conditions, and how well we are able to acquire or form strategic business alliances with local companies and make necessary infrastructure enhancements to production facilities and distribution networks. Our international operations also increase our compliance risks, including risks under the Foreign Corrupt Practices Act and other anti-corruption laws.
- Political conditions in international markets, including civil unrest, terrorist activity, governmental changes, trade barriers, restrictions on the ability to transfer capital across borders and governmental expropriation of assets. This includes the possible impact of the June 2016 advisory referendum by British voters to exit the European Union, which has created uncertainties affecting business operations in the United Kingdom and the EU.
- Deficit reduction efforts or other actions that reduce the availability of government funding for healthcare and research, which could weaken demand for our products and result in additional pricing pressures, as well as create potential collection risks associated with such sales.
- Fluctuations in university or U.S. and international governmental funding and policies for life sciences research.
- Fluctuations in the demand for products we sell to pharmaceutical companies that are used to manufacture, or are sold with, the products of such companies, as a result of funding constraints, consolidation or otherwise.
- The effects of events that adversely impact our ability to manufacture our products (particularly where production of a product line is concentrated in one or more plants) or our ability to source materials or components from suppliers (including sole-source suppliers) that are needed for such manufacturing.
- Pending and potential future litigation or other proceedings adverse to BD, including antitrust, product liability, environmental and patent infringement, and the availability or collectability of insurance relating to any such claims.
- New or changing laws and regulations affecting our domestic and foreign operations, or changes in enforcement practices, including laws relating to trade, monetary and fiscal policies, taxation (including tax reforms that could adversely impact multinational corporations), sales practices, environmental protection, price controls, and licensing and regulatory requirements for new products and products in the postmarketing phase. In particular, the U.S. and other countries may impose new requirements regarding registration, labeling or prohibited materials that may require us to re-register products already on the market or otherwise impact our ability to market our products. Environmental laws, particularly with respect to the emission of greenhouse gases, are also becoming more stringent throughout the world, which may increase our costs of operations or necessitate changes in our manufacturing plants or processes or those of our suppliers, or result in liability to BD.
- Product efficacy or safety concerns regarding our products resulting in product recalls, regulatory action on the part of the U.S. Food and Drug Administration (FDA) or foreign counterparts, declining sales and product liability claims, particularly in light of the current regulatory environment, in which there has been increased enforcement activity by the FDA. As a result of the CareFusion acquisition, we are operating under a consent decree with the FDA relating to our U.S. infusion pump business. The consent decree authorizes the FDA, in the event of any violations in the future, to order us to cease manufacturing and distributing products, recall products or take other actions, and we may be required to pay significant monetary damages if we fail to comply with any provision of the consent decree.
- Risks relating to our acquisition of CareFusion, including our ability to successfully combine and integrate the CareFusion operations in order to obtain the anticipated benefits and costs savings from the transaction, and the significant additional indebtedness we incurred in connection with the financing of the acquisition and the impact this increased indebtedness may have on our ability to operate the combined company.
- The effect of adverse media exposure or other publicity regarding BD’s business or operations, including the effect on BD’s reputation or demand for its products.
- The effect of market fluctuations on the value of assets in BD’s pension plans and on actuarial interest rate and asset return assumptions, which could require BD to make additional contributions to the plans or increase our pension plan expense.
- Our ability to obtain the anticipated benefits of restructuring programs, if any, that we may undertake.
- Issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission.

The foregoing list sets forth many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider this list to be a complete statement of all potential risks and uncertainties.

## Controls and procedures

As filed, 1,027 characters.

An evaluation was carried out by BD’s management, with the participation of BD’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of BD’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as of December 31, 2016. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the design and operation of these disclosure controls and procedures were, as of the end of the period covered by this report, effective and designed to ensure that material information relating to BD and its consolidated subsidiaries would be made known to them by others within these entities. There were no changes in our internal control over financial reporting during the fiscal quarter ended December 31, 2016 identified in connection with the above-referenced evaluation that have materially affected, or are reasonably likely to materially affect, BD’s internal control over financial reporting.

## Risk factors

As filed, 172 characters.

There were no material changes in the risk factors previously disclosed in Part I, Item 1A, of our 2016 Annual Report on Form 10-K during the period covered by this report.

Filed Feb 2, 2017.
Source: SEC EDGAR, the filing index for accession 0000010795-17-000002. Last ingested by Listed: Nov 11, 2026, 03:43 ET. No prices; not investment advice.
